177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials

被引：0
|
作者：
Bongiovanni, A. [1 ]
Nicolini, S. [2 ]
Foca, F. [3 ]
Sansovini, M. [2 ]
Grassi, I. [2 ]
Liverani, C. [1 ]
Riva, N. [1 ]
Fausti, V. [1 ]
Mercatali, L. [1 ]
De Vita, A. [1 ]
Fabbri, L. [3 ]
Signoretti, M. [4 ]
Pacilio, C. A. [5 ]
Paganelli, G. [2 ]
Severi, S. [2 ]
Ibrahim, T. [1 ]
Tartaglia, A. [6 ]
机构：
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Osteoncol & Rare Tumor Ctr, Meldola, Italy
[2] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Nucl Med & Radiometabol Unit, Meldola, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Unit Biostat & Clin Trials, Meldola, Italy
[4] Morgagni Pierantoni Hosp, Unit Gastroenterol & Digest Endoscopy, Forli, Italy
[5] Morgagni Pierantoni Hosp, Gen & Oncol Surg, Forli, Italy
[6] Morgagni Pierantoni Hosp, Unit Endocrinol, Forli, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1103P
引用
收藏
页码：S912 / S912
页数：1
相关论文
共 50 条
  • [41] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [42] NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors
    Elf, Anna-Karin
    Bernhardt, Peter
    Hofving, Tobias
    Arvidsson, Yvonne
    Forssell-Aronsson, Eva
    Wangberg, Bo
    Nilsson, Ola
    Johanson, Viktor
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 288 - 292
  • [43] 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
    Fross-Baron, Katarzyna
    Garske-Roman, Ulrike
    Welin, Staffan
    Granberg, Dan
    Eriksson, Barbro
    Khan, Tanweera
    Sandstrom, Mattias
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2021, 111 (04) : 330 - 343
  • [44] Safety and Efficacy of 177Lu-DOTATATE in Children and Young Adult Population
    Aggarwal, Piyush
    Satapathy, Swayamjeet
    Sood, Ashwani
    Singh, Harmandeep
    Mittal, Bhagwant Rai
    Lal, Sadhna
    Gupta, Rajesh
    Das, Chandan Krushna
    Yadav, Thakur Deen
    Walia, Rama
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : e312 - e318
  • [45] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [46] COST-EFFECTIVENESS ANALYSIS OF RE-TREATMENT WITH 177LU-DOTATATE VERSUS NO RE-TREATMENT WITH 177LU-DOTATATE IN PATIENTS WITH PROGRESSIVE MIDGUT NEUROENDOCRINE TUMORS
    Leeuwenkamp, O.
    Mahon, R.
    Singh, M. K.
    Khare, A.
    VALUE IN HEALTH, 2020, 23 : S446 - S446
  • [47] A multicenter phase 2 randomised controlled trial comparing 177Lu-Dotatate and capecitabine combination treatment with 177Lu-Dotatate in neuroendocrine tumor patients
    Becx, M.
    Hofland, J.
    Nonnekens, J.
    Krenning, E.
    Wyld, D.
    Verburg, F.
    Brabander, T.
    de Herder, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S122 - S123
  • [48] Radiological, clinical, scintigraphic and serum markers response of advanced neuroendocrine tumors treated with 177Lu-DOTATATE
    Mitjavila Casanovas, M.
    Percovich, J.
    Bello, P.
    Pubul, V.
    Arbizu, J.
    Muros, M.
    Garcia-Carbonero, R.
    Rotger, A.
    Gonzalez, E.
    Llana, B.
    Marin, M.
    Field, C.
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S594 - S594
  • [49] Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
    Sansovini, Maddalena
    Severi, Stefano
    Ambrosetti, Alice
    Monti, Manuela
    Nanni, Oriana
    Sarnelli, Anna
    Bodei, Lisa
    Garaboldi, Lucia
    Bartolomei, Mirco
    Paganelli, Giovanni
    NEUROENDOCRINOLOGY, 2013, 97 (04) : 347 - 354
  • [50] Dosimetry of 177Lu-DOTATATE administered into neuroendocrine tumors - An initial experience from India
    Gupta, Santosh
    Meera, V
    Malhotra, A.
    Kumar, Prateek
    Bal, Chandersekhar
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
12345